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Treatment with sumatriptan 50 mg in the mild
phase of migraine attacks in patients with
infrequent attacks: a randomised, double-blind,
placebo-controlled study






Abstract Most migraine patients
with infrequent attacks are cur-
rently not treated with migraine-
specific medication such as trip-
tans. The response of these
patients to triptans is unknown.
The objective of this study was to
investigate the efficacy and tolera-
bility of sumatriptan 50 mg vs.
placebo in migraine patents with
infrequent migraine attacks when
medication is taken during the
mild phase of an attack. The study
design was double-blind, placebo-
controlled, parallel-group and ran-
domised. Migraine patients were
recruited by general practitioners
and referred to one of 4 study cen-
tres. Additional patients were
recruited by advertising. The
patients were eligible for the
study if they had between 6 and
12 migraine attacks with or with-
out aura per year. The patients
were instructed to take the med-
ication during the mild phase of a
single attack. The primary effica-
cy measure was the percentage of
patients pain-free after 2 h. Forty-
six percent of treated attacks were
moderate or severe. In the inten-
tion-to-treat analysis, sumatriptan
was superior (20/51 patients were
pain-free) to placebo (8/47
patients pain-free) (p=0.03).
Adverse events (AEs) occurred
more frequently after sumatriptan
(40%) than after placebo (13%)
(p=0.003) and most AEs were
mild or moderate. In this migraine
population with infrequent
attacks, sumatriptan was superior
to placebo and was generally well
tolerated.
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Sumatriptan and other triptans have proved useful in the
treatment of migraine attacks, both with respect to effica-
cy and tolerability [1–5]. In the majority of randomised
controlled trials on triptans, migraine patients with a high
frequency of attacks, typically more than one per month,
were included, and treatment was initiated when headache
was moderate or severe. This group of patients, rather
experienced with migraine, was targeted, because a rea-
sonably brief time between screening and intake of study
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drug, as well as a high degree of certainty that genuine
migraine attacks and not other types of headache was
treated, have been priorities. This strategy leaves a group
of patients having less frequent attacks with less substan-
tial documentation of efficacy and tolerability of triptans.
The same patient group is likely to be a major fraction of
the large part of migraine patients that do not treat attacks
with triptans [6], and the poor evidence of benefit from
triptans in these patients may be one of several motives
for doctors recommending alternative drugs such as over-
the-counter drugs for their migraine. In addition, these
patients often do not consult for migraine.
As frequently pointed out in the recent literature, there
may be good arguments for treating migraine attacks
while the headache intensity is still mild [7, 8], although
this has been challenged [9]. Retrospective analyses of
sumatriptan data have suggested that treatment in the mild
headache phase is associated with higher pain-free rates
than when treatment is initiated at higher headache inten-
sity [10] and a prospective study showed that sumatriptan
was effective when given at the first sign of pain [11].
Finally, it has been suggested that central sensitisation
may occur quickly during migraine attacks, being
detectable as allodynia on the skin of the head [12], and
that such sensitisation diminishes the triptan effect [8].
Finally, using an analogy to episodic and chronic tension-
type headache where clearly more signs of central sensiti-
sation are found in the chronic than in the episodic form
[13], it may be speculated that migraine patients with rare
attacks would experience excellent effect from triptans.
We therefore conducted a prospective randomised
placebo-controlled study on the efficacy and tolerability
of sumatriptan in the mild phase of migraine in patients
with not more than 6–12 attacks per year.
Patients and methods
Inclusion and exclusion criteria
Patients were eligible for the study if they were between 18 and
65 years of age, suffered from migraine with or without aura as
defined by the 1988 International Headache Society criteria
(IHS) [14] for at least a year, had a history of 6–12 migraine
attacks per year, had the experience that the headache became
moderate or severe following a mild phase, were able to differ-
entiate migraine from other headaches and had not treated a
migraine with a triptan within the last 6 months.
Patients were excluded if they had uncontrolled hypertension
(diastolic blood pressure >95 mmHg or systolic blood pressure
>160 mmHg); had cardiovascular disease; suffered from chron-
ic tension-type headache [14]; had ophthalmoplegic, basilar and
hemiplegic migraine; or had suspected or confirmed cerebrovas-
cular or cardiovascular disease.
Study procedures
Patients were recruited by general practitioners (GPs) while
seeking assistance for headaches or other problem. The patients
were screened using a questionnaire based on the IHS criteria,
based on which the patients were screened. The GPs were
instructed to check the inclusion and exclusion criteria to make
sure the patients were eligible to enter the study. The GPs then
faxed names and addresses to the headache centre. All the
patients were hereafter contacted by phone and re-screened. Due
to a slow inclusion rate, advertising in local newspapers was ini-
tiated to provide a sufficient number of patients.
Patients who fulfilled the inclusion and exclusion criteria at
the screening visit were randomised to receive either sumatrip-
tan 50 mg or placebo in the ratio 1:1. They were randomised in
blocks of 6. After randomisation the patients had 5 months to
treat a migraine attack. They were instructed to treat the attack
within one hour after the attack started, but only if the attack was
still in the mild headache phase. Patients who experienced com-
plete pain relief two hours after intake of study medication could
take a second dose if they experienced a recurrent headache that
was moderate to severe 2–24 h after intake of the first dose.
Alternatively, they could use their usual medication.
Patients who did not experience complete pain relief after 2
h could take rescue medication. Triptans or ergotamine were not
allowed within 24 h after test medication.
Efficacy and tolerability measures
The primary efficacy measure was the percentage of patients
pain-free two hours after intake of study medication.
The secondary efficacy measures were:
- The percentage of patients who were pain-free 30 min and 1
h after intake of study medication.
- The percentage of patients who were pain-free 2–24 h after
intake of study medication.
- The percentage of patients without accompanying symptoms
(nausea, vomiting, phonophobia and photophobia) 30 min, 1
and 2 h after intake of study medication.
- The percentage of patients using rescue medication from 2 to
24 h.
- The percentage of patients who used a second dose of study
medication or other anti-migraine drug within 24 h of the
first dose of study medication.
- The percentage of patients satisfied with study medication.
- Number of hours away from work/education or social activ-
ities.
- The occurrence and severity (mild, moderate or severe) of
adverse events (AEs).
Statistical methods
A sample size of 58 subjects in each treatment group was sup-
posed to give at least 80% power (β) under the assumption that
25% of patients given placebo would be pain-free at 2 h vs. 50%
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given sumatriptan. A two-sided test and a significance level (α)
at 5% were assumed. Furthermore, it was assumed that approxi-
mately 20% of the subjects would not be able to treat a migraine
attack during the study period. Hence it would be necessary to
randomise a total of 146 subjects.
Statistical analyses of the proportion of patients pain-free
and other efficacy measures were done with Fisher’s exact test.
p<0.05 was chosen as the significance level.
The safety population included all subjects who took study
medication. The intention-to-treat (ITT) population included
subjects from the safety population who provided at least one
post-dose efficacy assessment. Missing data from the 30-min, 1-
and 2-h time points were not imputed. The ITT population con-
sisted of patients treated with investigational product and who
had efficacy data.
Ethical approval
The study protocol was approved by the local ethics committees.
Written, informed consent was obtained prior to inclusion.
Results
Patients’ characteristics and recruitment
Disposition of study subjects is shown in Figure 1. One hun-
dred and fifty-eight patients were screened and 150 patients
were randomised. Of these, 49 (33%) patients did not
receive study medication [17 lost to follow-up, and 32 had
no opportunity to treat in the 5 months study period (Fig. 1)].
The demographic and baseline characteristics in the
ITT population are shown in Table 1.
Treated attacks
In the placebo group there were 11 attacks of migraine
with aura and 33 attacks of migraine without aura (2
attacks had missing aura information) whereas in the
sumatriptan group there were 12 attacks of migraine with
aura and 40 attacks of migraine without aura.
A summary of headache pain scores (no pain, mild,
moderate and severe) at the start of the headache and
before the first dose for treated attacks is shown in Table
2. Before the first dose, 46% of subjects (45 of 98) had
moderate or severe pain across both treatment groups.
In the placebo group 6 patients (13%) were severely
impaired (2/5) or required bed rest (4/1)) whereas this was
the case for 6 patients (12%) in the sumatriptan group.
The scale was a 5-point scale: not at all, mild, moderate,
severe, bed rest required.
Before intake of study medication 69% in the placebo


































Fig. 1 Disposition of study subjects
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from nausea. For photophobia the percentages were 80%
and 61%, and for phonophobia the percentages were 49%
and 35%, respectively.
Efficacy
In the ITT population 20 of 51 (39%) patients treated with
sumatriptan were pain-free after 2 h whereas this was the
case in 8 of 45 (18%) patients treated with placebo [dif-
ference 21%; 95% confidence interval (CI): +4%–+39%;
p=0.03, Fisher’s exact test, see Table 2]. In the per proto-
col (PP) population (the patients with mild headache) 14
of 30 (47%) patients treated with sumatriptan were pain-
free after 2 h whereas this was the case in 6 of 22 (27%)
patients treated with placebo (difference 20%; 95% CI:
–6%–+45%; p=0.3, Fisher’s exact test). In the ITT and PP
population there was no difference between treatment
groups for pain-free after 30 min and 1 h, and no differ-
ence concerning photo- and phonophobia, and nausea.
In the ITT population more patients had a sustained
pain-free response after sumatriptan (15/46) (33%) than
after placebo (5/39) (13%) (difference 20%, 95% CI
+3%–+37%; p=0.06, Fisher’s exact test); in the PP popu-
lation the difference was 23% (sumatriptan (11/28) (39%)
and placebo (3/19) (16%) (95%CI: –1%–+48%; p=0.16,
Fisher’s exact test).
Study medication satisfaction
In the ITT population 22/53 patients (42%) treated with
sumatriptan were satisfied or very satisfied with the study
medication in general whereas this was only the case in
Table 1 Demographics and baseline characteristics (ITT population)
Placebo (n=48) Sumatriptan 50 mg (n=52)
Number of subjects Total 48 53
Males Number (%) 8 (17%) 14 (26%)
Females Number (%) 40 (83%) 39 (74%)
Age
Males [years] Mean (SD) 48 (10) 40 (12)
Females [years] Mean (SD) 36 (11) 36 (9)
Migraine with aura Number (%) 4 (8%) 7 (13%)
Migraine without aura Number (%) 40 (83%) 41 (77%)
Migraine with and without aura Number (%) 4 (8%) 5 (9%)
Previous triptans Number (%) 5 (10%) 7 (13%)
Concurrent medications Number (%) 36 (75%) 31 (59%)
Table 2 Summary of the level of pain (ITT population)
Time Placebo (n=48) Sumatriptan 50 mg (n=53)
No pain Mild Moderate Severe No pain Mild Moderate Severe
At migraine start 3 36 6 1 45 7
Missing values 2 1
Before first dose 22 22 2 31 21
Missing values 2 1
30 minutes after 1 15 26 3 3 21 26 2
Missing values 3 1
1 hour after 3 19 17 6 7 18 21 4
Missing values 3 3
2 hours after 8 9 18 10 20 14 12 5
Missing values 3 2
Missing values (MV) not imputed in table
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7/48 (15%) of patients treated with placebo. In the PP
population 16/31 patients (52%) treated with sumatriptan
were satisfied or very satisfied with the study medication
in general whereas this was only the case in 5/22 (23%) of
patients treated with placebo.
In the ITT population the median number of hours away
from work/education was 4.8 h (min-max: 0.5–12.0 h) in
the placebo group and 5.3 h (min-max: 1.0–16.0 h) in the
sumatriptan group. Median hours away from social activity
was 6.5 h (min-max: 1.5–40.0 h) in the placebo group and
3.0 h (min-max: 1.0–48.0 h) in the sumatriptan group.
Tolerability
In total there were 54 AEs reported, 10 after placebo and
44 after sumatriptan (see Table 3). The number of patients
with any AE was higher after sumatriptan (27/53, 51%)
than after placebo (7/48, 15%) (difference 36%; 95%CI:
+20%–+53%; p=0.003; Fisher’s exact test). The most
common AEs were nausea (n=5), paraesthesia (n=4),
fatigue (n=3) and chest pressure sensation (n=2). Most
AEs were mild to moderate and of short duration.
Discussion
Methodological considerations
The aim of this study was to evaluate the efficacy and tol-
erability of sumatriptan 50 mg in a migraine population
normally not being treated with a triptan. Only 10%–13%
in the study population had previously used a triptan. The
inclusion criterion was infrequent migraine of 6–12 attacks
per year. The study population was therefore recruited by
GPs and by advertisement. As shown by the time absent
from work (median 5 h with maximum up to 16 h) and
hours away from social activity (median 6 and 3 h in the
placebo and sumatriptan groups, respectively, with maxi-
mum of 40–48 h), the societal impact of migraine is con-
siderable in this selected patient population, even when
they could use rescue medication after 2 h.
In addition, based on recent experience [7, 10, 11, 17,
18] demonstrating a higher treatment response (43% with
2.5 mg zolmitripan [7], from 51% to 66% with 50–100 mg
sumatriptan [11, 17, 19] and 70% with 10 mg rizatriptan
[18]) when treating with a triptan in the mild phase of a
migraine attack, we instructed the patients to treat in the
mild phase of their attacks. In contrast, previous trials
[1–5] instructed the patients to wait until the pain was
moderate or severe and subsequently low response rates
for pain-free after 2 h, i.e., 28% [1] were found. In real life
patients are also more likely to start treatment at the
beginning of a migraine attack.
The patients were instructed to treat the migraine
attack within one hour of its start, but only if the attack
was still in the mild headache phase. Despite this, almost
half the patients treated an attack when the headache was
moderate or severe (Table 2). The most likely explanation
is that this was not the kind of patient normally participat-
ing in randomised controlled trials. They were not accus-
tomed to filling out headache diaries and being treated as
instructed in a clinical trial.
Results of this study
In this study 38% (95CI: 25%–53%) of patients in the ITT
population were pain-free after 2 h. In studies with suma-
triptan 50 mg with similar designs 51% [17], 50% [11]
and 51% [19] of patients were pain-free after 2 h, but in
these studies all patients were treated in the mild phase of
headache. In patients treating moderate/severe attack the
pain-free rate was 28% with sumatriptan 50 mg [1]. In our
study half the patients treated moderate/severe attacks and
the results for pain-free are in between the results from
these studies [1, 11, 17, 19].
Our hypothesis that these patients with relatively infre-
quent migraine attacks would be easier to treat could thus
not be proved. Furthermore it was surprising that 49
patients (almost 33%) did not treat an attack within the
Table 3 Patients with AEs in the ITT population
Treatment Severity
Mild Moderate Severe
Sumatriptan 50 mg Patients with AEs (n=27) 13 10 4
Number of AEs 44 19 19 6
Placebo Patients with AEs (n=7) 1 5 1
Number of AEs 10 1 8 1
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timelines, revealing that this patient group is reluctant to
treat their migraines with migraine-specific drugs before
they are sure that it is a real migraine attack.
In terms of tolerability, sumatriptan resulted in more AEs
than placebo. Most AEs were, however, mild and moderate.
In conclusion, sumatriptan 50 mg is effective in treat-
ing migraine patients with a frequency of less than 1
attack per month, and sumatriptan is well tolerated. The
efficacy of sumatriptan, the profile of AEs and social
impact in this study are similar to other studies with more
severely afflicted patients.
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